Open access, Immune Cell Therapies and Immune Cell Engineering – Page 3

Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma

5 de November de 2025 by

Background
Glioblastoma (GBM) is an aggressive brain tumor associated with poor outcome and limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell surface antigens were shown to induce tumor regression in patients with GBM, …

Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance

24 de October de 2025 by

Background
Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable responses in B-cell acute lymphoblastic leukemia (B-ALL). However, the contribution of the tumor microenvironment to the therapeutic response after CAR T-cell treatment r…

Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance

24 de October de 2025 by

Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and antitumoral activity upon IL-10 or TGF{beta} stimulation

15 de October de 2025 by Traxel, S., Schmidt, F., Beerli, C., Vuong, D.-V., Speck, R. F., Bredl, S.

Background
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks hormone receptors and human epidermal growth factor receptor 2 (HER2) amplification, making it unresponsive to standard hormone or HER2-targeted…

Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression

13 de October de 2025 by Li, W., Chen, J., Li, J., Wang, S., Chen, Z., Zhao, L., Zhao, Y., Gu, L., Liu, J., Zhang, Y., Yang, X., Chen, T., Guo, Z.

Background
Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable success in hematologic malignancies; however, its efficacy in solid tumors remains limited. A major barrier is the immunosuppressive tumor microenvironment (TME), wh…

Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors

10 de October de 2025 by

Background
Solid tumors comprise approximately 60% of all pediatric cancers. Relapsed or refractory tumors of the central nervous system (CNS), such as atypical teratoid/rhabdoid tumors (AT/RTs), are the leading cause of death in children with cancer….

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy

9 de October de 2025 by

Background
Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). However, a comprehensive analysis of germline deter…

Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors

9 de October de 2025 by Yang, S., Wang, W., Rao, Q., Xu, Y., Zhang, S., Qu, Y., Zhuang, Q., Mao, J., Sun, L., Geng, D., Xu, D., Zhao, C.

Background
Chimeric antigen receptor (CAR)-T cell therapy represents an innovative and potentially revolutionary modality in cancer treatment. Despite their great success in treating blood cancers, CAR-T therapies exhibit significantly lower effective…

Novel tetrameric bispecific KK-LC-1xCD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer

8 de October de 2025 by

Background
Cytokine-induced memory-like natural killer (CIML NK) cells demonstrate potent antitumor efficacy against hematological malignancies. Nevertheless, the therapeutic potential of adoptive NK cell transfer remains constrained in solid tumors d…

Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)

16 de September de 2025 by Restle, D., Amador-Molina, A., Misawa, K., Banerjee, S., Ku, G., Adusumilli, P. S.

Peritoneal carcinomatosis is a frequent metastatic condition in gastroesophageal cancer and is associated with poor prognosis and limited therapeutic options. Here, we establish clinically relevant mouse models of peritoneal carcinomatosis to evaluate…

301 Moved Permanently